Effect of Probiotics on Infantile Colic Symptoms

Exclusion Criteria

• •E1. Birthweight \< 2500 g. E2. Gestational age \< 37 weeks. E3. Apgar score at 5 minutes \< 7. E4. Partially or fully formula fed infants except for the 4 first days after birth.
• •E5. Stunted growth/weight loss (\< 100 g/week from birth to last reported). E6. Gastroesophageal reflux disease, short bowel syndrome, chronic intestinal diseases, or gastrointestinal malformations.
• •E7. Diagnosed or reported fever and/or infectious diseases, or current systemic infections, or history of congenital infections.
• •E8. Genetic diseases and chromosomal abnormalities. E9. Metabolic diseases or pancreatic insufficiency. E10. Immunodeficiency. E11. Neurological diseases. E12. Suspected or confirmed food allergies and intolerances. E13. Mother who consumed antacid medications (proton pump inhibitor and H2 receptor antagonist) within the month before birth and intend to consume any during the trial.
• •E14. Use of probiotics, prebiotics, antibiotics, or gastric acid inhibitors by the infant at any time from birth to the moment of screening and during the trial.
• •E15. Use of anti-colic medication at any time from birth to the moment of screening.
• •E16. Use of probiotics and prebiotics supplements by the mother between the birth of their infant and the moment of screening and intend to consume any during the trial.
• •E17. Currently enrolled in another clinical study or having participated in another clinical from birth to the moment of screening.
• •E18. Whose legal representatives have psychological or linguistic incapability to sign the informed consent.
• •E19. Impossibility to contact the legal representatives in case of emergency.